Until recently, Mikaela Knapp worked as an account director at San Francisco’s SparkPR. For the past six months, she’s been receiving treatment for an aggressive form of kidney cancer. She is 25 years old.
Her husband, her co-workers and her colleagues in the industry hope that new drugs currently being developed by the major pharmaceutical companies will help her fight her disease—and they’ve gone social with their appeal to Merck and other manufacturers.
Knapp’s husband Keith’s Change.org petition, created to convince Merck, Genentech and/or Bristol-Meyers Squibb to include her in a “compassionate use” clinical trial of these new drugs as soon as possible, is on its way to meeting its goal. Thanks at least in part to Knapp’s colleagues at Spark, it has also received media coverage via both local TV stations and tech blogs like VentureBeat and Pando Daily.
“We fully understand the risks with experimental medicine, but we have nothing to lose and much to gain. Your signature and those of your network will help us publicize our story and hopefully one of these companies will bite at the chance to be involved in the #WeGotThis community.”
[Pic via Keith Knapp]
- Biggest Stories of the Week
- Big Changes in Tech Journalism: 'Fake Steve Jobs' Is Your New Valleywag
- The Ticker: T-Mobile PR Revamp; No Firings at Uber; New Facebook Feature; And More
- MSNBC Names Former White House Staffer as VP of Communications